<DOC>
	<DOCNO>NCT00197119</DOCNO>
	<brief_summary>To evaluate persistence anti-hepatitis A virus ( anti-HAV ) anti-hepatitis B surface antigen ( anti-HBs ) antibodies 6 , 7 , 8 , 9 10 year administration first dose study vaccine .</brief_summary>
	<brief_title>Long-Term Follow-Up Studies Year 6 , 7 , 8 , 9 , 10 : 2 Formulations Combined Hepatitis A/B Vaccine Compared Subjects Aged 12-15 Years</brief_title>
	<detailed_description>Open , randomize , long-term antibody persistence study . Immune persistence compare subject receive one two formulation GlaxoSmithKline Biologicals ' combine hepatitis A hepatitis B vaccine accord two-dose three-dose schedule . These long-term follow-up study involve take blood sample approximately 6 , 7 , 8 , 9 10 year primary vaccination combine hepatitis A B vaccine , ass antibody persistence retrospective safety follow-up . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Healthy male female volunteer vaccinate study HAB084 . Written inform consent obtain subject blood sample visit year . • none</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>TWINRIX™ Adult</keyword>
	<keyword>Hepatitis A</keyword>
	<keyword>TWINRIX™ Junior</keyword>
</DOC>